Lv52
900 积分 2022-05-11 加入
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
5天前
已完结
Challenges in neoantigen-directed therapeutics
13天前
已完结
Active dissemination of cellular antigens by DCs facilitates CD8+ T‐cell priming in lymph nodes
19天前
已完结
Cross-presentation by dendritic cells
19天前
已完结
MHC class I antigen presentation: learning from viral evasion strategies
19天前
已完结
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
20天前
已完结
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
20天前
已完结
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
20天前
已完结
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
21天前
已完结
Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
26天前
已完结
皖公网安备34019202002308
